Reviewing Gamida Cell (NASDAQ:GMDA) & TrovaGene (NASDAQ:TROV)

Share on StockTwits

Gamida Cell (NASDAQ:GMDA) and TrovaGene (NASDAQ:TROV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings for Gamida Cell and TrovaGene, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gamida Cell 0 0 6 0 3.00
TrovaGene 0 0 2 0 3.00

Gamida Cell currently has a consensus target price of $18.50, indicating a potential upside of 279.88%. TrovaGene has a consensus target price of $14.50, indicating a potential upside of 747.95%. Given TrovaGene’s higher possible upside, analysts clearly believe TrovaGene is more favorable than Gamida Cell.

Valuation & Earnings

This table compares Gamida Cell and TrovaGene’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gamida Cell N/A N/A -$52.93 million ($10.53) -0.46
TrovaGene $380,000.00 27.82 -$16.46 million ($8.26) -0.21

TrovaGene has higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a lower price-to-earnings ratio than TrovaGene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gamida Cell and TrovaGene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gamida Cell N/A -429.90% -110.45%
TrovaGene -3,424.46% -149.88% -105.52%

Insider & Institutional Ownership

25.9% of Gamida Cell shares are owned by institutional investors. Comparatively, 11.1% of TrovaGene shares are owned by institutional investors. 2.0% of TrovaGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

TrovaGene beats Gamida Cell on 8 of the 11 factors compared between the two stocks.

Gamida Cell Company Profile

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

TrovaGene Company Profile

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.